Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 5/20 | 0.44 |
| ▸ | ITGA2 | P17301 | 5/20 | 0.44 |
| ▸ | BACE1 | P56817 | 14/20 | 0.40 |
| ▸ | CTSD | P07339 | 5/20 | 0.36 |
| ▸ | CTSE | P14091 | 3/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881346 | 0.81 | BACE1 (0.48) | BACE1CTSDCTSE | |
| SCHEMBL4879235 | 0.73 | BACE1 (0.71) | BACE1CTSDCTSE | |
| SCHEMBL4878446 | 0.73 | BACE1 (0.57) | BACE1CTSDCTSE | |
| SCHEMBL4881777 | 0.72 | BACE1 (0.52) | BACE1CTSDCTSE | |
| SCHEMBL4872647 | 0.72 | ITGB1 (0.41) | ITGB1ITGA2BACE1CTSDCTSE | |
| SCHEMBL4872651 | 0.72 | ITGB1 (0.41) | ITGB1ITGA2BACE1CTSDCTSE | |
| SCHEMBL2346936 | 0.68 | ITGB1 (0.40) | ITGB1ITGA2BACE1CTSDPSMB8 | |
| SCHEMBL8318007 | 0.60 | BACE1 (0.90) | ITGB1ITGA2BACE1CTSD | |
| SCHEMBL22800184 | 0.56 | ITGB1 (0.43) | ITGB1ITGA2PSMB5 | |
| SCHEMBL27876786 | 0.53 | SMN1; SMN2 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | ITGB1 3026/4885ITGA2 4036/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.